Neonatal respiratory distress syndrome is a serious breathing problem affecting newborns, primarily those born too early. Understanding how doctors support tiny lungs that haven’t fully developed helps families navigate this challenging first chapter of their baby’s life.

Helping Tiny Lungs Take Their First Breaths

When a baby is born prematurely, their lungs may not be ready to breathe on their own. Neonatal respiratory distress syndrome, often shortened to RDS, happens when a newborn struggles to get enough oxygen shortly after birth. This condition is particularly common in babies born before 34 weeks of pregnancy, though it can occasionally affect full-term infants as well.^[1] The main goal of treating RDS is to help the baby breathe comfortably while their lungs continue to develop and strengthen.^[2]

Treatment approaches depend heavily on how early the baby was born and how severe their breathing difficulties are. Some babies need only mild support for a few days, while others born extremely early may require weeks of intensive care.^[3] Medical teams have several established treatments that have dramatically improved survival rates over recent decades. Beyond these standard approaches, researchers continue testing new therapies in clinical trials, searching for ways to make treatment even safer and more effective.^[1]

The condition develops because the baby’s lungs haven’t produced enough of a crucial substance called surfactant, which coats the tiny air sacs in the lungs and keeps them from collapsing. Without adequate surfactant, these air sacs cannot stay open to allow oxygen to enter the bloodstream. Babies typically begin producing surfactant around 24 to 28 weeks of pregnancy, but most don’t make sufficient amounts until about 34 to 35 weeks.^[4] When babies arrive before this milestone, their immature lungs struggle with every breath, leading to rapid, shallow breathing, grunting sounds, flared nostrils, and often a bluish tint to their skin from lack of oxygen.^[5]

Standard Treatment Methods for Breathing Support

The cornerstone of RDS treatment is providing extra oxygen to babies who cannot breathe adequately on their own. The amount of oxygen and the method of delivery depend on how severely the baby is affected. For mild cases, doctors may simply increase the oxygen concentration in the baby’s incubator, the enclosed, temperature-controlled bed where premature infants rest. Some babies receive oxygen through a small mask over their nose or face, or through tiny tubes placed just inside the nostrils, called a nasal cannula.^[2]

A widely used technique is continuous positive airway pressure, or CPAP. This method gently pushes a continuous flow of air or oxygen through tubes in the baby’s nose, creating just enough pressure to keep the tiny air passages open. Think of it like holding a balloon partially inflated—the constant gentle pressure prevents it from completely deflating. CPAP has become extremely popular because it often prevents the need for more invasive breathing support.^[3] Many hospitals now start CPAP immediately in the delivery room for premature babies who can breathe on their own but need assistance keeping their airways open.^[5]

When RDS is more severe, babies may need a ventilator, a breathing machine that does much of the breathing work for them. To use a ventilator, doctors carefully insert a soft tube through the baby’s mouth into their windpipe in a procedure called intubation. The ventilator then pushes air into the lungs at controlled intervals. While ventilators can be lifesaving, medical teams try to avoid them when possible because the pressure and mechanical breathing can potentially damage delicate lung tissue over time.^[3]

Perhaps the most significant breakthrough in RDS treatment has been surfactant replacement therapy. This treatment involves giving babies artificial surfactant directly into their lungs through a breathing tube. The surfactant medication comes from animal lungs or is made synthetically in laboratories. When delivered into the airways, it immediately begins coating the air sacs, helping them stay open and function more normally.^[6] Research has shown that surfactant therapy is most effective when started within the first two hours after birth.^[4] The standard dose is typically 100 milligrams per kilogram of the baby’s weight, though some studies suggest starting with 200 milligrams per kilogram may work even better, improving oxygen levels and reducing the need for repeat doses.^[5]

A technique called INSURE—which stands for intubate, administer surfactant, and extubate to nasal CPAP—has become increasingly popular. With this approach, doctors briefly place a breathing tube, give the surfactant medication quickly, and then remove the tube and immediately switch the baby to CPAP support. This minimizes the time spent on mechanical ventilation while still delivering the crucial surfactant treatment.^[5] Studies compiled in systematic reviews show that INSURE reduces complications like air leaks in the lungs and may help prevent chronic lung damage.^[16]

Beyond breathing support, babies receive comprehensive care including careful monitoring of body temperature, nutrition delivered through tubes connected to veins, and close observation of fluid balance. Medical teams regularly check blood oxygen and carbon dioxide levels through blood tests, adjusting treatment as needed. Infections can complicate RDS, so doctors watch carefully for signs of bacterial infection and treat promptly with antibiotics when necessary.^[3]

Prevention Before Birth

One of medicine’s greatest successes in preventing RDS happens before the baby is even born. When doctors know a woman will likely deliver before 34 weeks of pregnancy, they can give her injections of corticosteroid medications such as betamethasone or dexamethasone. These powerful hormones cross the placenta and stimulate the baby’s lungs to mature more quickly and produce more surfactant.^[4]

The mother typically receives two doses, given 24 hours apart. This relatively simple intervention has proven remarkably effective—it’s estimated that antenatal corticosteroids prevent RDS in about one out of every 11 babies who would otherwise develop the condition.^[5] The treatment also reduces other serious complications of prematurity and significantly improves survival rates. Medical guidelines strongly recommend this preventive treatment for threatened preterm deliveries between 24 and 34 weeks of pregnancy.^[13]

Some women at risk of early delivery may also receive magnesium sulfate to reduce the risk of developmental problems in babies born very early. However, prolonged use of magnesium sulfate requires careful monitoring, as extended treatment in rare cases has been associated with bone problems in newborns.^[4]

Promising Therapies Being Tested in Clinical Trials

While current treatments have greatly improved outcomes, researchers continue exploring new approaches that might work even better. Clinical trials test experimental therapies to determine if they are safe and whether they improve results compared to standard treatment. These studies happen in phases, each answering different questions about a new treatment.

Much current research focuses on refining surfactant therapy. Scientists are testing different types of surfactant preparations to see which works best. Natural surfactants extracted from animal lungs contain proteins and fats that closely mimic human surfactant. Synthetic versions are manufactured in laboratories to specific formulations. Early studies using synthetic surfactant called Exosurf Neonatal and trials with animal-derived preparations have been compared in multiple research trials.^[16] Results from combined analysis of six major studies involving over 3,500 infants showed that early surfactant treatment—given within the first two hours of life—significantly reduced deaths compared to delayed treatment. Early treatment also lowered the risk of dangerous air leaks around the lungs, a complication that can occur in about 5 percent fewer babies when surfactant is given promptly.^[16]

Researchers are also investigating the optimal timing and dosing of surfactant. Some trials examine whether giving surfactant preventively in the delivery room to extremely premature babies works better than waiting until RDS symptoms develop. Others compare different surfactant doses or test whether additional doses beyond the first treatment provide extra benefit without increasing risks.^[12]

Beyond surfactant, trials explore advanced ventilation techniques. High-frequency oscillatory ventilation, or HFOV, uses extremely rapid, tiny breaths rather than normal-sized breaths. This approach may reduce lung damage in severe cases. Studies in Germany found that about one-third of newborns with severe respiratory failure needed HFOV, with approximately 60 percent showing improvement.^[12] This specialized ventilation method is being refined through ongoing research to determine which babies benefit most.

Nitric oxide is a gas that, when inhaled, helps blood vessels in the lungs relax and open up, improving oxygen delivery. It’s particularly useful when babies develop persistent pulmonary hypertension, a condition where high blood pressure in the lung arteries restricts blood flow. Studies found that inhaled nitric oxide helped about half of newborns who received it, making it a valuable option for complicated cases.^[12] Trials continue examining exactly which babies benefit most from this therapy and at what doses.

In extreme cases where other treatments fail, extracorporeal membrane oxygenation, or ECMO, may be considered. This is essentially a heart-lung bypass machine for babies, taking over the work of oxygenating blood outside the body. German researchers found that among babies sick enough to potentially need ECMO, the treatment achieved an 80 percent survival rate.^[12] However, ECMO requires very specialized equipment and expertise, so it’s only available at major medical centers and is reserved for the most critical situations.

Clinical trials for RDS treatments take place at major hospitals around the world, including in the United States, Europe, and other regions. Babies may be eligible to participate if they meet specific criteria regarding their gestational age, birth weight, and severity of illness. Parents interested in clinical trials should discuss options with their baby’s medical team, who can explain any trials happening at their hospital and whether participation might be appropriate.

Most Common Treatment Methods

• Oxygen Therapy
  • Nasal cannula with small tubes placed in nostrils for oxygen delivery
  • Oxygen hood placed over baby’s head in the incubator
  • Mask over nose and face for increased oxygen concentration
  • Careful monitoring to avoid complications from too much oxygen
• Continuous Positive Airway Pressure (CPAP)
  • Noninvasive breathing support using tubes in the nose
  • Gentle pressure keeps airways from collapsing
  • Often started immediately in the delivery room for premature babies
  • Reduces need for mechanical ventilation
  • Nasal bubble CPAP is one commonly used variation
• Mechanical Ventilation
  • Breathing machine for babies with severe RDS who cannot breathe adequately
  • Requires intubation with soft tube inserted through mouth into windpipe
  • Ventilator controls breathing rate and oxygen delivery
  • Used when baby has very low oxygen, high carbon dioxide, or repeated breathing pauses
  • Settings gradually reduced as baby improves to avoid lung damage
• Surfactant Replacement Therapy
  • Artificial surfactant delivered directly into lungs through breathing tube
  • Natural preparations from animal lungs or synthetic laboratory-made versions
  • Most effective when given within first two hours after birth
  • Standard dose is 100 mg per kg, higher doses may provide additional benefit
  • INSURE technique combines brief intubation, rapid surfactant delivery, and quick switch to CPAP
• Antenatal Corticosteroids
  • Steroid injections given to mother before premature delivery
  • Two doses typically given 24 hours apart
  • Stimulates baby’s lung development and surfactant production
  • Recommended between 24 and 34 weeks gestation for threatened preterm labor
  • Prevents RDS in about one in 11 at-risk babies
• Supportive Care
  • Temperature control in special warmers or incubators
  • Nutrition through intravenous lines when baby cannot feed
  • Fluid balance management
  • Infection prevention and treatment with antibiotics when needed
  • Close monitoring with frequent blood tests to check oxygen, carbon dioxide, and other levels
• High-Frequency Oscillatory Ventilation (HFOV)
  • Specialized ventilation using very rapid, tiny breaths
  • Used in severe cases or when conventional ventilation is insufficient
  • May reduce lung injury compared to standard ventilators
  • About 60 percent of babies show improvement with this method
• Inhaled Nitric Oxide
  • Gas treatment that relaxes blood vessels in the lungs
  • Helps improve oxygen delivery
  • Particularly useful for persistent pulmonary hypertension complications
  • Effective in approximately 50 percent of treated babies

Recovery and What to Expect

The course of RDS follows a somewhat predictable pattern. Symptoms typically worsen during the first two to four days after birth as the baby’s body works to produce more surfactant naturally. After this initial period, most babies begin to improve gradually.^[3] Babies with mild disease who don’t require mechanical ventilation often recover within five to seven days and can breathe room air without extra oxygen relatively quickly.^[24]

Recovery takes longer for babies born extremely early or those with more severe disease requiring high levels of oxygen and ventilator support. These infants may need respiratory assistance for weeks or even months.^[2] The smallest babies, those weighing less than two and a half pounds at birth, face the slowest recovery. Complications such as infection or air leaks in the lungs can also delay healing.^[24]

As babies improve, medical teams gradually reduce support. Oxygen concentrations are lowered step by step with the goal of reaching room air levels (21 percent oxygen). CPAP pressure is decreased and eventually stopped. For babies on ventilators, doctors slowly change machine settings to let the baby do more breathing work independently before removing the breathing tube entirely.^[24]

Most premature babies with RDS can eventually go home around the time of their original due date, though some may need supplemental oxygen or other support after discharge. Length of hospital stay depends primarily on how early the baby was born and whether complications developed.^[4]

Supporting Parents Through the Journey

Watching your newborn struggle to breathe is extraordinarily difficult for parents. The neonatal intensive care unit can feel overwhelming with its machines, monitors, alarms, and medical terminology. Medical teams understand this stress and work to provide not just physical care for babies but emotional support for families as well.^[12]

Parents are encouraged to participate in their baby’s care as much as possible, even during treatment. Many hospitals promote gentle handling, creating calm environments, and maintaining ideal body temperature—all factors that help babies heal.^[3] Skin-to-skin contact, called kangaroo care, may be possible once babies are stable enough, strengthening the parent-child bond during recovery.

Hospital staff can answer questions about what’s happening and what to expect. Understanding the treatments, seeing gradual improvements, and celebrating small milestones—like reducing oxygen needs or taking first breaths without CPAP—helps families cope during the challenging early days. Parent support groups, either in the hospital or online, connect families facing similar experiences, providing understanding and practical advice from those who’ve been through it.